Virologic response at week 8 of combined treatment as a predictor of sustained virologic response in non rapid virologic response, chronic HCV genotype 4 infected patients

Egyptian Journal of Medical Human Genetics

Volumn 13, Issue 3, 2012, Pages 331-335

  Monis, Ali ^a   Ali Monis, Ahmed ^a   Al Swaff, Reham ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Genotype 4; HCV; RVR; SVR; Week 8

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; PREDICTIVE VALUE; RAPID VIROLOGIC RESPONSE; SENSITIVITY AND SPECIFICITY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

HEPATITIS C VIRUS;

EID: 84900367498     PISSN: 11108630     EISSN: 20902441     Source Type: Journal    
DOI: 10.1016/j.ejmhg.2012.03.002     Document Type: Article

References (20)

1. Nguyen M.H., Keeffe E.B. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005, 3(l 2):S97-S101.
2. Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report; 2007. Available from http://www.mohp.gov.eg/Main.asp.
3. Abdel-Aziz F., Habib M., Mohamed M.K., et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000, 32:111-115.
4. Dienstag J.L., McHutchison J.G. Management of hepatitis C. Gastroenterology 2006, 130:225-230.
5. Jensen D.M., Morgan T.R., Marcellin P., et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006, 43:954-960.
6. Zeuzem S., Buti M., Ferenci P., et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97-103.
7. Shiffman M.L., Suter F., Bacon B.R., et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007, 357(2):124-134.
8. Ferenci P., Fried M.W., Shiffman M.L., et al. Predicting sustained virologic responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005, 43(3):425-433.
9. Chevaliez S., Pawlotsky J.M. Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. Int J Med Sci 2006, 3(2):35-40.
10. Sandrin L., Taner M., Ctheline S., et al. Shear modulus imaging with 2-D transient elastography. IEEE Trans Ultrasound Ferro Freq Control Soc 2002, 27(12):1261-1268.
11. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterolgy 2005, 128:343-350.
12. Dimitroulopoulos D., Elefsiniotis I., Pavlidis C., et al. European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: The role of rapid and early virologic response. Hepat Mon 2010, 10(3):193-198.
13. Hadziyannis S.J., Sette H., Morgan T.R., et al. Peginterferona2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004, 140(5):346-355.
14. Lee S.S., Heathcote E.J., Reddy K.R., et al. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J Hepatol 2002, 37(4):500-506.
15. Roulot D., Bourcier V., Grando V., et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007, 14(7):460-467.
16. Marcellin P, Jensen DM, Hadziyannis SJ, et al. Differentiation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin (COPEGUS). AASLD, November 2-6, Boston, USA; 2007.
17. Marcellin P, Hadziyannis SJ, Berg T, et al. Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alfa-2a (40KD) plus ribavirin. EASL, April 11-15, Barcelona, Spain; 2007.
18. Ferenci P., Laferl H., Scherzer T.M., et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008, 135(2):451-458.
19. Davis G.L., Wong J.B., McHutchison J.G., et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645.
20. Manns M.P., McHutchison J.G., Gordon S.C., et al. Pegylated interferon alpha-2b plus ribavirin compared with interferon-alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001, 358:958-965.